The Peptide App.
Pepty delivers personalized protocol tracking, smart reminders, progress monitoring, and essential tools to support your peptide research.
Pepty is live on the App Store.
Everything peptides, in your pocket.
- 68 compounds with real-time vendor pricing
- Protocol scheduling with smart reminders
- Reconstitution calculator, half-life charts, interaction checker
- AI research assistant
- Price comparison across 15+ vendors (save up to $1,000/yr)
We want to be your go-to app for peptides, we have a lot of features/improvements shipping at light speed.
https://t.co/07CgQcKKIB
survodutide Phase 3 results just dropped.
16.6% body weight loss. dual GLP-1/glucagon receptor agonist.
why this matters: glucagon activation means it's not just appetite suppression. it's actively increasing energy expenditure.
different mechanism. different ceiling. keep an eye on this one.
What’s new:
• Learn lessons are now fully translated into 12 languages
• Refined dashboard, tools, and profile screens in both light and dark mode
• Smoother quizzes
• HUGE UI improvements and additional bug fixes
the weight loss peptide race right now:
• semaglutide — the OG, proven, generic now available
• tirzepatide — dual agonist, arguably stronger results
• retatrutide — triple agonist, Phase III, could be the next leap
• survodutide — 16.6% weight loss in Phase 3
we're watching pharma move faster than regulators can keep up. the next 12 months will be wild.
July 2026. FDA's PCAC hearing on peptide reclassification.
12 peptides potentially leaving Category 2: BPC-157, MOTS-C, GHK-Cu, KPV, Semax, Epitalon, TB-500...
this could reshape the entire research peptide landscape. compounding pharmacies, vendors, researchers — everyone's watching.
are you paying attention?
the peptide vendor reply section under any popular BPC-157 post is a masterclass in why this industry needs better standards.
half the accounts replying have no COAs, no third-party testing, and domains registered 3 months ago.
if your vendor can't show you a certificate of analysis with batch-specific results, that's not a vendor. that's a gamble.
Peptides are not miracle drugs!
I built a site that grades them against the data.
46 peptides. 419 citations. community-voted tier list.
not medical advice. not selling you anything on this site.
I love peptides and there's too much BS on socials about em... go see the information for yourself.
https://t.co/m884i7aHcy
retatrutide is entering Phase III trials and nobody's talking about it enough.
semaglutide hits one receptor. tirzepatide hits two. retatrutide hits three.
this could make both of them obsolete. keep your eye on the TRIUMPH program data.
FDA just removed 12 peptides from Category 2. BPC-157, TB-500, MOTS-C, Semax, Epitalon, GHK-Cu, KPV.
sounds like good news right?
not so fast. they still need to pass the July PCAC hearing to get back on the legal compounding list. this is step 1 of 3.
the peptide space has an honesty problem.
half the accounts posting about BPC-157 and TB-500 are selling it to you. the other half are just repeating what the sellers said.
Pepty doesn't sell peptides. we're just the data. 🧬